SCHEMBL622339

SCHEMBL622339

CC(C)COc1cc(N2CCN(C(=O)c3cccc4nnsc34)CC2)ncn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 4/20 0.36
HSD17B10 Q99714 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
GBA1 P04062 1/20 0.36
MAPT P10636 1/20 0.35
MGLL Q99685 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
HPGD P15428 3/20 0.34
LMNA P02545 3/20 0.34
GAA P10253 2/20 0.34
RAB9A P51151 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
TSHR P16473 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SCD O00767 2/20 0.34
NPC1 O15118 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623275 0.78 MAPK14 (0.48) MAPTMGLLGAA
SCHEMBL623239 0.77 ALDH1A1 (0.52) ALDH1A1MAPTSMN1; SMN2LMNAGAA
SCHEMBL623230 0.77 NAAA (0.49) ALDH1A1KDM4EHSD17B10CYP2C9CYP2C19
SCHEMBL624636 0.76 ALDH1A1 (0.58) ALDH1A1HSD17B10MAPTSMN1; SMN2HPGD
SCHEMBL624496 0.76 TSHR (0.53) ALDH1A1KDM4EMAPTMGLLSMN1; SMN2
SCHEMBL623189 0.76 PTK2 (0.51) MGLLGAATSHRMEN1KMT2A
SCHEMBL624750 0.76 LMNA (0.47) ALDH1A1KDM4EHSD17B10CYP2C9CYP2C19
SCHEMBL623267 0.76 KCNK3 (0.43) ALDH1A1KDM4EHSD17B10CYP2C19SMN1; SMN2
SCHEMBL624539 0.75 MGLL (0.44) ALDH1A1KDM4EMAPTMGLLSMN1; SMN2
SCHEMBL623746 0.75 KCNK3 (0.43) MAPTSMN1; SMN2LMNARAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G ALDH1A1 2071/4885KDM4E 1537/4885HSD17B10 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.